ConductScience.org, home

Paper26320063

Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Lipson EJ and 5 others. Semin Oncol, 2015. Cited by 245 papers, by iCite.

Cite this record

ConductScience Library. Antagonists of PD-1 and PD-L1 in Cancer Treatment. Papers, record 26320063. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26320063

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antagonists of PD-1 and PD-L1 in Cancer Treatment.
PubMed
Journal
Semin Oncol
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
245
iCite
Relative citation ratio, by iCite
7.28
iCite
Revised in PubMed
2022-04-08
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lipson EJEvan J
2Forde PMPatrick M
3Hammers HJHans-Joerg
4Emens LALeisha A
5Taube JMJanis M
6Topalian SLSuzanne L

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
B7-H1 AntigenMajor topic
NeoplasmsMajor topic
Programmed Cell Death 1 ReceptorMajor topic
Biomarkers, Tumor
Humans
Immunosuppression Therapy
Tumor Microenvironment

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 CA142779NCI NIH HHSUnited StatesR01CA142779PubMed and NIH
R01CA142779NCI NIH HHSUnited StatesR01CA142779PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124608200Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.Ann Oncol2014https://conductscience.org/library/papers/24608200PubMed
224590637Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J Clin Oncol2014https://conductscience.org/library/papers/24590637PubMed
324714771Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.Clin Cancer Res2014https://conductscience.org/library/papers/24714771PubMed
425384885Identification and management of toxicities from immune checkpoint-blocking drugs.Oncology (Williston Park)2014https://conductscience.org/library/papers/25384885PubMed
525428503MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.Nature2014https://conductscience.org/library/papers/25428503PubMed
625428504Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature2014https://conductscience.org/library/papers/25428504PubMed
724831977
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol2014https://conductscience.org/library/papers/24831977PubMed
824842267Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.Breast Cancer Res Treat2014https://conductscience.org/library/papers/24842267PubMed
924658839Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.Cancer Immunol Immunother2014https://conductscience.org/library/papers/24658839PubMed
1025428505PD-1 blockade induces responses by inhibiting adaptive immune resistance.Nature2014https://conductscience.org/library/papers/25428505PubMed
1125409260Genetic basis for clinical response to CTLA-4 blockade in melanoma.N Engl J Med2014https://conductscience.org/library/papers/25409260PubMed
1225358689The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.Cancer Discov2015https://conductscience.org/library/papers/25358689PubMed
1325399552Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med2015https://conductscience.org/library/papers/25399552PubMed
1425482239PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.N Engl J Med2015https://conductscience.org/library/papers/25482239PubMed
1525524312Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.Clin Cancer Res2015https://conductscience.org/library/papers/25524312PubMed
1625452452Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.J Clin Oncol2015https://conductscience.org/library/papers/25452452PubMed
1712529460Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.N Engl J Med2003https://conductscience.org/library/papers/12529460PubMed
1817159987Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.Nat Med2007https://conductscience.org/library/papers/17159987PubMed
1917360651Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.Proc Natl Acad Sci U S A2007https://conductscience.org/library/papers/17360651PubMed
2019825956Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.Clin Cancer Res2009https://conductscience.org/library/papers/19825956PubMed

See all 40 referencesDownload CSV of references

Cited by171

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 245 citations.

PMIDTitleJournalYearIn PapersSource
42854695Spatially tuned localization of interleukins and OX40 agonists enhances synergistic anti-tumor immunity.Cell Rep Med2026https://conductscience.org/library/papers/42854695PubMed
42287338Neuropeptide Y as a Neuro-Immune Checkpoint in Cancer.J Neuroimmune Pharmacol2026https://conductscience.org/library/papers/42287338PubMed
41674937Development and validation of a herb-related gene signature for prognosis prediction and therapeutic response assessment in breast cancer.Transl Cancer Res2026https://conductscience.org/library/papers/41674937PubMed
41518478LncRNA PVT1 drives macrophage polarization and triple-negative breast cancer progression via PPARγ-mediated transcriptional activation​.Apoptosis2026https://conductscience.org/library/papers/41518478PubMed
41228268Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients.Cancers (Basel)2025https://conductscience.org/library/papers/41228268PubMed
40847228Recent Advancements in Immunotherapy for the Treatment of Metastatic Breast Cancer.Cancer Treat Res2025https://conductscience.org/library/papers/40847228PubMed
40502964A comprehensive review of using nanomaterials in cancer immunotherapy: Pros and Cons of clinical usage.3 Biotech2025https://conductscience.org/library/papers/40502964PubMed
40444482Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review).Int J Oncol2025https://conductscience.org/library/papers/40444482PubMed
40075663Immune Cell Interplay in the Fight Against GBM.Cancers (Basel)2025https://conductscience.org/library/papers/40075663PubMed
40073258Immune suppression sustained allograft acceptance requires PD1 inhibition of CD8+ T cells.J Immunol2025https://conductscience.org/library/papers/40073258PubMed
40060757Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy.Bioeng Transl Med2025https://conductscience.org/library/papers/40060757PubMed
40040557
Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study.
Int J Urol2025https://conductscience.org/library/papers/40040557PubMed
39966234The chick embryo chorioallantoic membrane as an experimental model to study immune checkpoint inhibitors.Intern Emerg Med2025https://conductscience.org/library/papers/39966234PubMed
39246446Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy.iScience2024https://conductscience.org/library/papers/39246446PubMed
39109293The Groebke-Blackburn-Bienaymé reaction in its maturity: innovation and improvements since its 21st birthday (2019-2023).Beilstein J Org Chem2024https://conductscience.org/library/papers/39109293PubMed
39011666Deciphering the tumour microenvironment of clear cell renal cell carcinoma: Prognostic insights from programmed death genes using machine learning.J Cell Mol Med2024https://conductscience.org/library/papers/39011666PubMed
38625861Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease.PLoS One2024https://conductscience.org/library/papers/38625861PubMed
38553754Exploring the dynamic interplay between exosomes and the immune tumor microenvironment: implications for breast cancer progression and therapeutic strategies.Breast Cancer Res2024https://conductscience.org/library/papers/38553754PubMed
38203846Programmed Cell Death Ligand 1 Immunohistochemical Expression and Cutaneous Melanoma: A Controversial Relationship.Int J Mol Sci2024https://conductscience.org/library/papers/38203846PubMed
38201238Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.Cells2023https://conductscience.org/library/papers/38201238PubMed

See all 171 cited byDownload CSV of cited by

Genes16

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26320063

GET https://conductscience.org/api/papers/v1/26320063/references?page=2